BridgeBio Pharma
BridgeBio Pharma is a biotechnology company dedicated to the development of innovative therapies for genetic diseases and cancers with clear genetic drivers. Founded in 2015 and headquartered in Palo Alto, California, the company has established a robust pipeline of 20 development programs, featuring a range of product candidates from early discovery to late-stage clinical trials. Notable projects include BBP-265, an oral small molecule for the treatment of transthyretin amyloidosis, and infigratinib, a selective tyrosine kinase inhibitor aimed at addressing FGFR-driven cancers and achondroplasia. Additionally, the company is developing BBP-631, a gene transfer product for congenital adrenal hyperplasia, and BBP-454, a program targeting KRAS-driven cancers. BridgeBio collaborates with various academic institutions and research organizations to enhance its R&D efforts and accelerate the development of transformative medicines for patients with high unmet medical needs.
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
PellePharm develops patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in phase 2 clinical trial for the treatment of sporadic BCCs.
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.
MyoKardia is a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing targeted therapies for the treatment of rare cardiovascular diseases. The company's focus is on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It utilizes its medicine platform to generate an initial pipeline of therapeutic programs for the chronic treatment of the two most common forms of heritable cardiomyopathy-hypertrophic cardiomyopathy and dilated cardiomyopathy. The company was founded in 2012 and is headquartered in Brisbane, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.